Insider sale details
Adaptive Biotechnologies (NASDAQ: ADPT) Chief Scientific Officer Harlan S. Robins sold a total of 42,788 shares of the company’s common stock over two trading days - February 2 and February 3, 2026 - realizing approximately $799,104 from the transactions.
According to a Form 4 filing with the Securities and Exchange Commission, the shares were sold at weighted average prices spanning from $18.26 to $19.38. On February 2, Robins sold 34,668 shares in a series of transactions at prices between $18.26 and $18.88. On February 3, he sold 8,120 shares in multiple tranches at prices that ranged from $18.56 to $19.38.
These sales took place close to the company’s 52-week high of $20.76. An InvestingPro analysis noted in the filing suggests the shares could be trading above their Fair Value.
Following the dispositions, Robins directly holds 1,179,524 shares of Adaptive Biotechnologies. The filing states the trades were conducted pursuant to a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025.
Company performance and corporate developments
Adaptive Biotechnologies reported a strong financial performance for 2025, with total revenue rising roughly 55% to approximately $277 million for the year. The company’s fourth-quarter revenue was about $72 million, marking a 51% increase compared with the same quarter in 2024 and exceeding analyst expectations of $59.4 million.
Revenue from the company’s Minimal Residual Disease (MRD) business expanded notably, with full-year MRD revenue reaching $212 million, a 46% increase year over year.
Strategically, Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer focused on T-cell receptor discovery and immune data licensing. Those deals include potential milestone payments that could amount to up to $890 million.
On the financing front, the company disclosed that its subsidiary, Digital Biotechnologies, has begun a Series A Preferred Stock financing round that is expected to raise up to $15 million.
Investment banking coverage remains supportive: Piper Sandler has reiterated an Overweight rating and a $20 price target on Adaptive Biotechnologies, noting expectations for what the firm describes as a potential landmark financial year in 2026.
Context and takeaway
The insider sales by Robins were executed under a pre-established trading plan and occurred in the context of strong company revenue growth, expanding MRD sales, strategic collaborations with Pfizer, and active subsidiary financing. The filing and company disclosures provide the factual record of ownership, transaction mechanics, and recent financial and corporate milestones.
Readers should rely on the filings and company statements for additional detail; the sale and corporate developments above are presented as reported in the company’s disclosures.